Barbexaclone

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 447439675

| image = Barbexaclone.svg

| image_class = skin-invert-image

| type = combo

| component1 = Phenobarbital

| class1 = Barbiturate

| component2 = Levopropylhexedrine

| class2 = Sympathomimetic

| tradename =

| Drugs.com = {{drugs.com|international|barbexaclone}}

| pregnancy_category =

| legal_BR = B1

| legal_BR_comment = {{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=Diário Oficial da União |language=pt-BR |publication-date=2023-04-04}}

| legal_US = Schedule IV

| legal_status =

| routes_of_administration =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 4388-82-3

| ATC_prefix = N03

| ATC_suffix = AA04

| PubChem = 71196

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB09001

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 64332

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 291GX1YB65

}}

Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine.{{cite book| vauthors = Shorvon S, Perucca E, Engel Jr J |title=The Treatment of Epilepsy |url= https://books.google.com/books?id=ppKbCgAAQBAJ&pg=PT1706 |date=23 September 2015 |publisher=Wiley |isbn=978-1-118-93699-3 |pages=1706–1707 }} It was introduced in 1965. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results"{{cite journal | vauthors = Salles Barbosa MF | title = [Barbexaclone in the treatment of cerebral dysrhythmia] | journal = Arquivos de Neuro-Psiquiatria | volume = 36 | issue = 3 | pages = 245–249 | date = September 1978 | pmid = 28716 | doi = 10.1590/s0004-282x1978000300009 | doi-access = free }} had not yet been confirmed nor denied in controlled trials.